EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy

Panneerselvam Theivendren iD, Selvaraj Kunjiappan iD, Parasuraman Pavadai iD, Kaveena Ravi, Anusuya Murugavel, Avinash Dayalan, A Santhana Krishna Kumar

ACS Measurement Science Au · 19.02.2025 · 5 (1) · 31-55

DOI: 10.1021/acsmeasuresciau.4c00062 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ACS Measurement Science Au, online erschienen am 15.11.2024. Verfasst von Panneerselvam Theivendren und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Swamy Vivekanandha College of Pharmacy, Elayampalayam 637205, Namakkal, Tamil Nadu, India. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy is an innovative way of treating cancer by stimulating individual cells to overcome cancer. Widespread biomedical studies were carried out with the aim of exploring immunotherapy cancer therapeutics, and this review spotlights some mechanisms in which it was developed, namely immune checkpoint inhibitors (E.G PD-1/PD-L1, CTLA-4), adoptive cell therapy (e.g., CAR T-cell therapy), and cancer vaccines. Although it has shown clinical benefit in a number of cancer types, including melanoma and non-small-cell lung cancer, several challenges have dampened enthusiasm for this approach, from the differing patient response rates to toxicities. Nanotechnology in drug delivery systems must play a role in overcoming the same. Nanotechnology enables increased specificity and controlled drug release, improved solubility and bioavailability, can treat the tumor specifically, and localized drug delivery at the disease site decreases systemic toxicity. The review also features advances in the construction of lipid-based, polymeric, and inorganic nanoparticles that improve drug stability and allow the delivery of cotherapeutic agents. Nanotechnology-based delivery systems can be used alone or in combination with immunotherapy to assist in improving the immune response, gaining access to the tumor microenvironment, and overcoming biological barriers. Thus, the nano-DDS were both safe and effective in preclinical studies, and ongoing clinical trials have shown that they are capable of increasing the therapeutic index of anticancer drugs. Lastly, the review also discusses current challenges and regulatory issues in advancing these technologies and highlights the importance of further research to devise appropriate methodology for efficient functionalization of nanotechnology for individualized cancer solutions in cancer treatment.

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Swamy Vivekanandha College of Pharmacy, Elayampalayam 637205, Namakkal, Tamil Nadu, India.
  • Department of Biotechnology, Kalasalingam Academy of Research and Education, Krishnankoil 626126, Tamil Nadu, India.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, M. S. R. Nagar, Bengaluru 560054, Karnataka, India.
  • Department of Pharmaceutics, Swamy Vivekananda College of Pharmacy, Elayampalayam 637205, Namakkal, Tamil Nadu, India.
  • Center for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Chennai 602105, Tamil Nadu, India.
  • Department of Chemistry, National Sun Yat-sen University, No. 70, Lien-hai Road, Gushan District, Kaohsiung City 80424, Taiwan.

ORCID-Profile: Panneerselvam Theivendren, Selvaraj Kunjiappan, Parasuraman Pavadai

Zitieren

APA

Theivendren, P., Kunjiappan, S., Pavadai, P., Ravi, K., Murugavel, A., Dayalan, A., & Santhana Krishna Kumar, A. (2025). Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy. ACS Measurement Science Au, 5(1), 31-55. https://doi.org/10.1021/acsmeasuresciau.4c00062

Vancouver

Theivendren P, Kunjiappan S, Pavadai P, Ravi K, Murugavel A, Dayalan A, et al. Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy. ACS Measurement Science Au. 2025;5(1):31-55. doi:10.1021/acsmeasuresciau.4c00062

BibTeX
@article{Theivendren2025,
  author = {Theivendren, Panneerselvam and Kunjiappan, Selvaraj and Pavadai, Parasuraman and Ravi, Kaveena and Murugavel, Anusuya and Dayalan, Avinash and Santhana Krishna Kumar, A},
  title = {Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy},
  journal = {ACS Measurement Science Au},
  year = {2025},
  volume = {5},
  number = {1},
  pages = {31--55},
  doi = {10.1021/acsmeasuresciau.4c00062}
}
Kostenlos starten →